Vulnerable COPD patients with comorbidities: the role of roflumilast

Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms “roflumilast” and “COPD”. Reference c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipari, Melissa, Kale-Pradhan, Pramodini B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242693/
https://www.ncbi.nlm.nih.gov/pubmed/25429225
http://dx.doi.org/10.2147/TCRM.S55105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4242693/
https://www.ncbi.nlm.nih.gov/pubmed/25429225
http://dx.doi.org/10.2147/TCRM.S55105

Ejemplares similares